EUVIMEDAtrasti EUVIMED
ÜbersichtsarbeitOpen access

Selective androgen receptor modulators in preclinical and clinical development

Ramesh Narayanan, Michael L Mohler, Casey E Bohl, Duane D Miller, James T Dalton

Nuclear Receptor Signaling · 2008-01 · 6 (1)

DOI: 10.1621/nrs.06010 ↗

At a glance

Übersichtsarbeit in Nuclear Receptor Signaling, published online on 2008-11-26. Written by Ramesh Narayanan and 4 co-authors. Institution: Preclinical Research and Development, GTx, Inc., Memphis, Tennessee, USA. Major MEDLINE topics: Drug Design. Cited 129 times so far (Crossref); 200 references. The full text is freely available in PubMed Central.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Androgen receptor (AR) plays a critical role in the function of several organs including primary and accessory sexual organs, skeletal muscle, and bone, making it a desirable therapeutic target. Selective androgen receptor modulators (SARMs) bind to the AR and demonstrate osteo- and myo-anabolic activity; however, unlike testosterone and other anabolic steroids, these nonsteroidal agents produce less of a growth effect on prostate and other secondary sexual organs. SARMs provide therapeutic opportunities in a variety of diseases, including muscle wasting associated with burns, cancer, or end-stage renal disease, osteoporosis, frailty, and hypogonadism. This review summarizes the current standing of research and development of SARMs, crystallography of AR with SARMs, plausible mechanisms for their action and the potential therapeutic indications for this emerging class of drugs.

Subjects

MeSH terms (MEDLINE)

Drug DesignAnimalsClinical Trials as TopicDrug Evaluation, PreclinicalHumansReceptors, Androgen

Substances

Receptors, Androgen

Authors and institutions

  • Preclinical Research and Development, GTx, Inc., Memphis, Tennessee, USA.

Cite

APA

Narayanan, R., Mohler, M. L., Bohl, C. E., Miller, D. D., & Dalton, J. T. (2008). Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 6(1). https://doi.org/10.1621/nrs.06010

Vancouver

Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling. 2008;6(1). doi:10.1621/nrs.06010

BibTeX
@article{Narayanan2008,
  author = {Narayanan, Ramesh and Mohler, Michael L and Bohl, Casey E and Miller, Duane D and Dalton, James T},
  title = {Selective androgen receptor modulators in preclinical and clinical development},
  journal = {Nuclear Receptor Signaling},
  year = {2008},
  volume = {6},
  number = {1},
  doi = {10.1621/nrs.06010}
}
Start for free →